{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:54:09Z","timestamp":1790870049396,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.rdc.2004.01.005","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"365-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"30","author":[{"given":"Stanley B","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2004.01.005_BIB1","series-title":"Rheumatoid arthritis, etiology, diagnosis and treatment","author":"Utsinger","year":"2002"},{"issue":"18","key":"10.1016\/j.rdc.2004.01.005_BIB2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780330302","article-title":"Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis","volume":"33","author":"Arend","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2004.01.005_BIB4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.rdc.2004.01.005_BIB5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/08830189809043005","article-title":"Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist","volume":"16","author":"Dinarello","year":"1998","journal-title":"Int Rev Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00002281-200105000-00004","article-title":"Anti-interleukin-1 therapy in rheumatic diseases","volume":"13","author":"Dayer","year":"2001","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0090-1229(90)90126-B","article-title":"Arthritis induced by interleukin-1 is dependent on the site and frequency of intraarticular injection","volume":"55","author":"Chandrasekhar","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"issue":"4","key":"10.1016\/j.rdc.2004.01.005_BIB8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.49.4.238","article-title":"Effects of murine recombinant interleukin 1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation","volume":"49","author":"van de Loo","year":"1990","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB9","first-page":"225","article-title":"Arthritis induced by continuous infusion of hr-interleukin-1 alpha into the rabbit knee-joint","volume":"11","author":"Feige","year":"1989","journal-title":"Int J Tissue React"},{"issue":"7","key":"10.1016\/j.rdc.2004.01.005_BIB10","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.4049\/jimmunol.159.7.3604","article-title":"Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis","volume":"159","author":"Ghivizzani","year":"1997","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4049\/jimmunol.141.3.834","article-title":"In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice","volume":"141","author":"Hom","year":"1988","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2004.01.005_BIB12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0090-1229(90)90072-X","article-title":"Interleukin 1 enhances the development of spontaneous arthritis in MRL\/lpr mice","volume":"55","author":"Hom","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"issue":"8613","key":"10.1016\/j.rdc.2004.01.005_BIB13","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0140-6736(88)90185-7","article-title":"Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis","volume":"2","author":"Eastgate","year":"1988","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2004.01.005_BIB14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00270301","article-title":"Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis","volume":"5","author":"Bendtzen","year":"1985","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.rdc.2004.01.005_BIB15","first-page":"295","article-title":"Cytokines and the chronic inflammation of rheumatic disease. I. The presence of interleukin-1 in synovial fluids","volume":"55","author":"Nouri","year":"1984","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.rdc.2004.01.005_BIB16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/art.1780310404","article-title":"Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction","volume":"31","author":"Miyasaka","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2004.01.005_BIB17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.191.2.313","article-title":"Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice","volume":"191","author":"Horai","year":"2000","journal-title":"J Exp Med"},{"issue":"5 Suppl 2","key":"10.1016\/j.rdc.2004.01.005_BIB18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/sarh.2001.23704","article-title":"Uncoupling of inflammatory and destructive mechanisms in arthritis","volume":"30","author":"van den Berg","year":"2001","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2004.01.005_BIB19","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1073\/pnas.95.8.4613","article-title":"Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects","volume":"95","author":"Ghivizzani","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB20","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4049\/jimmunol.149.3.1054","article-title":"IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium","volume":"149","author":"Firestein","year":"1992","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.005_BIB21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/rheumatology\/31.12.801","article-title":"Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage\/pannus junction in rheumatoid arthritis","volume":"31","author":"Deleuran","year":"1992","journal-title":"Br J Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/art.1780370507","article-title":"Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis","volume":"37","author":"Firestein","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB23","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1172\/JCI114622","article-title":"Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist","volume":"85","author":"Arend","year":"1990","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/1043-4666(91)90044-E","article-title":"Interaction of recombinant monocyte-derived interleukin 1 receptor antagonist with rheumatoid synovial cells","volume":"3","author":"Arend","year":"1991","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.rdc.2004.01.005_BIB25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.1780340112","article-title":"Biologic effects of an interleukin-1 receptor antagonist protein on interleukin-1-stimulated cartilage erosion and chondrocyte responsiveness","volume":"34","author":"Smith","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.005_BIB26","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.4049\/jimmunol.145.12.4181","article-title":"Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production","volume":"145","author":"Seckinger","year":"1990","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.rdc.2004.01.005_BIB27","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/S0021-9258(18)61450-4","article-title":"The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor","volume":"262","author":"Mosley","year":"1987","journal-title":"J Biol Chem"},{"issue":"6256","key":"10.1016\/j.rdc.2004.01.005_BIB28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/343336a0","article-title":"Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor","volume":"343","author":"Hannum","year":"1990","journal-title":"Nature"},{"issue":"6256","key":"10.1016\/j.rdc.2004.01.005_BIB29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/343341a0","article-title":"Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist","volume":"343","author":"Eisenberg","year":"1990","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB30","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A","article-title":"Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data","volume":"42","author":"Bendele","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.005_BIB31","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1128\/iai.59.12.4436-4442.1991","article-title":"Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats","volume":"59","author":"Schwab","year":"1991","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.rdc.2004.01.005_BIB32","first-page":"239","article-title":"Role of interleukin 1 in antigen-induced exacerbations of murine arthritis","volume":"146","author":"van de Loo","year":"1995","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen-induced arthritis in DBA\/1 mice. A comparative study using anti-TNF alpha, anti- IL-1 alpha\/beta, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2004.01.005_BIB34","series-title":"Kineret [package insert]","year":"2001"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.005_BIB35","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB36","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2004.01.005_BIB37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/art.10870","article-title":"Anakinra, a recombinant human interleukin-1 receptor antagonist (r- metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial","volume":"48","author":"Fleischmann","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2004.01.005_BIB38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","article-title":"A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores","volume":"43","author":"Jiang","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2004.01.005_BIB39","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/art.10578","article-title":"Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Nuki","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2004.01.005_BIB41","first-page":"225","article-title":"Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis","volume":"30","author":"Cohen","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2004.01.005_BIB42","series-title":"ACR\/ARHP Annual Scientific Meeting Program","first-page":"318","article-title":"Anakinra (Kineret) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis","author":"Shergy","year":"2002"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.005_BIB43","first-page":"273","article-title":"Anakinra (Kineret) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis","volume":"62","author":"Shergy","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.005_BIB45","first-page":"183","article-title":"Long-term safety of anakinra (interleukin-1 receptor antagonist) in patients receiving standard treatments for rheumatoid arthritis: a 2-year update from a large phase III study","volume":"62","author":"Fleischmann","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2004.01.005_BIB46","doi-asserted-by":"crossref","first-page":"768","DOI":"10.7326\/0003-4819-131-10-199911160-00009","article-title":"Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy","volume":"131","author":"Pincus","year":"1999","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.rdc.2004.01.005_BIB47","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"10.1016\/j.rdc.2004.01.005_BIB48","first-page":"S268","article-title":"Infections in rheumatoid arthritis","volume":"43","author":"Doran","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.rdc.2004.01.005_BIB49","first-page":"S343","article-title":"Safety of anakinra (interleukin-1 receptor antagonist) in rheumatoid arthritis (RA) subjects with potential high risk for infection","volume":"46","author":"Fleischmann","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.005_BIB50","first-page":"191","article-title":"Anakinra safety experience: Infection results from a long-term safety study and postmarketing experience","volume":"62","author":"Veith","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2004.01.005_BIB51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein","volume":"337","author":"Moreland","year":"1997","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2004.01.005_BIB52","first-page":"1238","article-title":"Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland","year":"2001","journal-title":"J Rheumatol"},{"issue":"8930","key":"10.1016\/j.rdc.2004.01.005_BIB53","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"issue":"9194","key":"10.1016\/j.rdc.2004.01.005_BIB54","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.rdc.2004.01.005_BIB55","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M","article-title":"Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis","volume":"43","author":"Bendele","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"10.1016\/j.rdc.2004.01.005_BIB56","first-page":"S79","article-title":"Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis","volume":"44","author":"Schiff","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.005_BIB57","first-page":"66","article-title":"A randomized double blind controlled study evaluating the safety and efficacy of etanercept vs. etanercept plus anakinra in patients with rheumatoid arthritis","volume":"62","author":"Genovese","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.rdc.2004.01.005_BIB58","first-page":"186","article-title":"An evaluation of the use of anakinra by rheumatoid arthritis patients previously treated with a TNF inhibitor","volume":"62","author":"Schiff","year":"2003","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X04000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X04000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:56:02Z","timestamp":1760180162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X04000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0889857X04000195"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2004.01.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2004.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}